Salarius Pharmaceuticals - through its subsidiary Decoy Therapeutics - is teaming up with the Martinez-Sobrido Lab at Texas Biomed to test novel peptide-conjugate fusion inhibitors across multiple influenza strains (including H5N1) in vitro. The Martinez-Sobrido Lab, renowned for its expertise in viral reverse genetics, beings world-class virology and viral-pathogenesis capabilities to evaluate Decoy IMP3ACT platform candidates. This collaboration represents a critical step toward developing a single antiviral that could combat respiratory viruses.
Read more about it here -> https://investors.salariuspharma.com/news-releases/news-release-details/salarius-pharmaceuticals-collaborate-texas-biomedical-research
https://www.sahmcapital.com/news/content/salarius-pharmaceuticals-to-collaborate-with-texas-biomedical-research-institute-on-avian-flu-study-2025-12-01